News

Jerusalem, Israel, January 2, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application(ANDA) to market its generic version of Dey's bronchodilator, DuoNeb® (Albuterol Sulfate and Ipratropium Bromide) Inhalation Solution, 3 mg (0.083%)and 0.5 mg (0.017%).Shipment of the product will begin immediately.The brand product had annual sales of approximately $265 million in the United States for the twelve months ended September 30, 2007, based on IMS sales dat Read More »

Jerusalem, Israel, January 3, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Applications (ANDA) to market its generic version of Roche's antinauseant and antiemetic agent Kytril® (Granisetron Hydrochloride) Injection, 1 mg (base)/mL in 1 mL single-dose vials and 1 mg (base) Tablets. Shipment of these products has commenced.As the first company to file an ANDA with a Paragraph IV patent certification for Granisetron Hydrochloride Injection, 1 mg (base)/m Read More »

Jerusalem, Israel, January 3, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) will host a live audio webcast at the Morgan Stanley Pharmaceutical CEOs Unplugged Conference in NY and the 26th Annual JPMorgan Healthcare Conference in San-Francisco. Dan Suesskind, Chief Financial Officer and Bill Marth, President & CEO Teva Pharmaceuticals USA will present at Morgan Stanley on Friday, January 4, 2008 and at JPMorgan on Monday, January 7, 2008. What: Teva Presentation at the Morgan Stanley Pharmaceutical CEOs Unplugged Conference in NY and the 26th ANNUAL JPMorgan Healthcare Conferenc Read More »

Jerusalem, Israel, January 10, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that George S. Barrett, Chief Executive Officer, Teva North America, Corporate Executive VP, Global Pharmaceutical Markets has resigned from the Company and that William S. Marth, currently President and Chief Executive Officer of Teva USA, will replace Mr. Barrett and assume the additional role of Chief Executive Officer of Teva North America effective immediately. Mr. Barrett, who is leaving to become Vice Chairman of Cardinal Health and CEO of its Healthcare Supply Chain Services Sector, Read More »

Jerusalem, Israel, January 14, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it is exploring strategic alternatives for its animal health business, including a possible divestiture. This decision follows the strategic review the Company conducted in 2007. Teva's animal health business develops, manufactures and markets proprietary and generic animal health products, principally in the U.S. and Israel, serving all major companion and farm animal segments with both prescription and over-the-counter products. The business also markets some of its products internati Read More »

Jerusalem, Israel, January 14, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Eisai's Alzheimer's treatment Aricept® (Donepezil Hydrochloride) Tablets, 5 mg and 10 mg. The brand product had annual sales of approximately $1.6 billion in the United States for the twelve months ended September 30, 2007, based on IMS sales data.Teva is currently in patent litigation concerning this product in the U.S. Distric Read More »

North Wales, Pa. and Atlanta, January 16, 2008 - Teva Specialty Pharmaceuticals, the U.S. respiratory therapy unit of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and UCB (Euronext: UCB) today announced an agreement to co-commercialize Teva's U.S. respiratory medicines. The initial product to be jointly promoted in the U.S. is Teva's ProAir®HFA (albuterol sulfate) Inhalation Aerosol. ProAir®HFA is the number-one branded hydrofluroalkane (HFA) albuterol sulfate inhaler in the U.S. Additionally, the agreement will provide UCB future joint promotion opportunities with other products in deve Read More »

Jerusalem, Israel, January 17, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Pravastatin Sodium Tablets, 80 mg. Teva's Pravastatin Sodium Tablets, 80 mg are the AB-rated generic equivalent of Bristol-Myers Squibb's Pravachol® 80 mg tablets, and are indicated for treatment of certain hyperlipidemias and the primary prevention of coronary events. Teva is already marketing the 10 mg, 20 mg and 40 mg strengths of this product.Total annual s Read More »

Jerusalem, Israel, January 22, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has entered into a definitive agreement to acquire CoGenesys, Inc., a privately-held biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories. CoGenesys was established in 2005 as a division within Human Genome Sciences Inc. (HGSI) to focus on early drug development and was spun off as an independent company in June 2006. In its recently completed strategic review, T Read More »

Jerusalem, Israel, January 22, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated December 24, 2007, the Company and Wyeth/Altana have agreed to extend their standstill agreement regarding generic Protonix® (Pantoprazole Sodium), through January 31, 2008. Under the agreement, Teva agreed not to ship additional product. This extension of the standstill period will allow the parties to continue their patent litigation settlement discussions.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutic Read More »